IX-001 is under clinical development by Immuxell Biotech and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IX-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IX-001 overview
The therapeutic candidate is under development for the treatment of solid tumors, advanced pancreatic cancer and colorectal cancer and pancreatic ductal adenocarcinoma. It comprises of T-cells genetically engineered to express T cell receptors (TCR) targeting mutant KRAS expressing tumor cells. It is administered through intravenous route.
Immuxell Biotech overview
Immuxell Biotech is a biomedical technology innovation company engaged in research and development of immunotherapy drugs for the treatment of solid tumors. The company is headquartered in Shanghai City, Shanghai, China.
For a complete picture of IX-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
